Pharmaceutical

Omalizumab biosimilar by Teva Pharmaceutical Industries for Chronic Urticaria Or Hives: Likelihood of Approval

Omalizumab biosimilar is under clinical development by Teva Pharmaceutical Industries and currently in Phase III for Chronic Urticaria Or Hives.

Jun 18, 2024 - 04:00
Omalizumab biosimilar is under clinical development by Teva Pharmaceutical Industries and currently in Phase III for Chronic Urticaria Or Hives.
Read the original article

Tags:

Previous Article

Olanzapine by Neurelis for Bipolar Disorder (Manic Depression): Likelihood of Ap...

Next Article

Olanzapine ER by Teva Pharmaceutical Industries for Schizophrenia: Likelihood of...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: PBMs were the target of House hearing, but pharma wasn’t spared criticism

STAT+: PBMs were the target of House hearing, but pharm...

Sep 20, 2023

STAT+: Pharmalittle: Biotech investors push to extend time before Medicare price negotiations; RiteAid closings could cause pharmacy deserts

STAT+: Pharmalittle: Biotech investors push to extend t...

Oct 18, 2023

Some hoped a new oral vaccine would solve all the polio campaign’s problems. Reality is settling in

Some hoped a new oral vaccine would solve all the polio...

May 27, 2023